Navigation Links
NKTR-102 Demonstrates Sustained Clinical Benefit in 46% of Patients with Metastatic Breast Cancer in Data Presented at 2011 American Society of Clinical Oncology Annual Meeting
Date:6/4/2011

he overall study population was 46%.  An additional four patients in the study had near CRs, with 100% disappearance of all target lesions.  

"NKTR-102 is emerging as a promising anti-cancer investigational treatment with the potential to become the first topoisomerase I-inhibitor to be used in the fight against breast cancer," said Prof. Ahmad Awada, Head of the Medical Oncology Clinic at the Institut Jules Bordet in Brussels, Belgium. "The drug's high confirmed objective response rate and clinical benefit is very interesting, particularly when one observes that this response rate was maintained in patients pre-treated with anthracyclines, taxanes with or without capecitabine, and also maintained in poor prognosis subsets within the study, such as triple-negative breast cancer and patients with visceral disease." 

The confirmed ORR in patients previously treated with anthracycline/taxane/capecitabine was 31% (5/16); confirmed ORR in patients with metastatic triple-negative breast cancer was 39% (7/18); and confirmed ORR in patients with visceral disease was 30% (17/57).  

"The every three week dose schedule appears well-tolerated overall and demonstrates encouraging PFS and OS of 5.3 months and 13.1 months, respectively," continued Dr. Awada.  "We are in need of effective new therapeutic options whose mechanism of action is different from those already available for women with metastatic breast cancer and we look forward to NKTR-102 entering Phase 3 development."

Patients treated in the single-agent NKTR-102 study had a median of two lines of prior cytotoxic treatments for metastatic disease.  Seventy-four percent (52/70) of the patients received neoadjuvant and/or adjuvant therapy and 86% (60/70) had visceral disease.  

"The clinical benefit we've observed in multiple tumor settings with NKTR-102, where a highly active topoisomerase 1 inhibitor could be extremely useful, makes us very excited a
'/>"/>

SOURCE Nektar Therapeutics
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Tumor Growth Inhibition and Pharmacokinetic Profile of NKTR-102 (PEG-Irinotecan) in Multiple Solid Tumors To Be Presented at Upcoming AACR-NCI-EORTC International Conference
2. NKTR-102 (PEG-Irinotecan) Demonstrates Significant Tumor Growth Inhibition In Multiple Preclinical Tumor Models
3. Nektar Commences Phase 2 Clinical Development Program for NKTR-102 (PEG-Irinotecan) in Colorectal Cancer
4. Additive Anti-Tumor Activity of NKTR-102 in Combination With Bevacizumab Highlighted in Positive Preclinical Data Presented at AACR Meeting
5. Significant Anti-Tumor Activity of NKTR-102 in Patients With Refractory Solid Tumors; Interim Data Published in ASCO 2008 Proceedings
6. Nektar to Webcast Presentation of Phase 1 Clinical Results for Lead Small Molecule PEG-Oncolytic Program, NKTR-102 (PEG-irinotecan)
7. Nektar Announces Expanded Phase 2 Clinical Development Plan For NKTR-102 (PEG-irinotecan)
8. NKTR-102 Shows Encouraging Anti-Tumor Activity in Ovarian Cancer in Phase 1 and Preclinical Data Presented at the ECCO 15 and 34th ESMO Multidisciplinary Congress
9. NKTR-102 Demonstrates Significant Efficacy as Single-Agent in Second- or Third-Line Treatment in Metastatic Breast Cancer Patients
10. FDA Grants Orphan Drug Designation for Nektars Investigational Drug, NKTR-102, for Treatment of Women with Ovarian Cancer
11. Nektar Announces New Phase 2 Data for NKTR-102 to Be Presented at 2011 ASCO Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2013)... May 21, 2013  NxStage Medical, Inc. (Nasdaq: ... products, today announced that it has entered into new ... in-center products to DaVita, the kidney care division of ... ) For the use of products for ... , NxStage has executed a second amended and restated ...
(Date:5/21/2013)... New data released today at the ... that the NeuroStar TMS Therapy System ® ... in patients with Major Depressive Disorder (MDD) during ... through one year of treatment.  At the end ... symptomatic improvement while 41 percent reported complete remission. ...
(Date:5/21/2013)... Quebec , May 21, 2013 ... (NYSE: VRX ) (TSX: ... ten directors nominated at its 2013 ... detailed results of the vote for ... out below:  NameForWithheldRonald H. Farmer235,731,9341,964,748Robert A. ...
Breaking Medicine Technology:NxStage Announces New Agreements with DaVita 2New Data Show Long-Term Benefit of Transcranial Magnetic Stimulation in Difficult-to-Treat Patients with Depression using NeuroStar TMS Therapy System 2New Data Show Long-Term Benefit of Transcranial Magnetic Stimulation in Difficult-to-Treat Patients with Depression using NeuroStar TMS Therapy System 3New Data Show Long-Term Benefit of Transcranial Magnetic Stimulation in Difficult-to-Treat Patients with Depression using NeuroStar TMS Therapy System 4Valeant Pharmaceuticals Announces 2013 Annual Meeting Results 2
... Astellas Pharma US, Inc. ("Astellas") recently hired Mark ... oncology. Reporting directly to Patrick Shea, senior vice ... responsible for all U.S. commercial activities supporting marketed ... lead commercial planning for early stage development compounds. ...
... The Targetech Innovation Center, supported by a strategic ... developing pipeline of biomedical device opportunities poised to begin ... "This is an exciting development in the strategic ... effort, we will see more companies locating to Akron. ...
Cached Medicine Technology:Astellas Announces Vice President of Sales and Marketing for U.S. Oncology Franchise 2Akron Relationship with Israeli Incubator, Targetech, Shows Promise 2Akron Relationship with Israeli Incubator, Targetech, Shows Promise 3
(Date:5/21/2013)... 2013 Phoseon Technology will present their ... 20th Annual IMI European Ink Jet Conference (June ... Phoseon continues to invest in product development to enable ... UV LED curing in printing applications. Phoseon currently ... market offering both air cooled and water cooled solutions ...
(Date:5/21/2013)... (PRWEB) May 21, 2013 Modern ... the help of Texas Counseling’s Sexuality and Relationship ... and the development of healthier habits for their ... available for both couples and individuals at Texas ... their relationships and learn skills to develop long ...
(Date:5/21/2013)... Repository (DoDSR), University of Cincinnati (UC) researchers have identified ... which could help with earlier diagnosis and intervention in ... finding, the first of its kind and led by ... presentation by staff from Walter Reed National Military Medical ... 18-21 in Orlando, Fla. , The DoDSR is ...
(Date:5/21/2013)... May 21, 2013 The Las Vegas personal ... to announce that Crawford Gates, a senior at Coronado High ... college scholarship essay contest . As the winner of the ... essay contest started on Dec. 1, 2012 and ran through ... to submit a three-page minimum essay on “The Role of ...
(Date:5/21/2013)... A new study appearing in the ... stem cells harvested from fat (adipose) are more potent ... modulate the body’s immune system. , The finding ... as adipose tissue-derived stem cells (AT-SCs) are far more ... marrow and can be collected from waste material from ...
Breaking Medicine News(10 mins):Health News:Workshops Offered To Identify Underlying Challenges That Put Strain On Relationships 2Health News:Biomarkers discovered for inflammatory bowel disease 2Health News:Benson, Bertoldo, Baker & Carter is Pleased to Announce the Winner of its First Annual College Scholarship Essay Contest 2Health News:Stem Cells from Fat Outperform Those from Bone Marrow in Fighting Disease 2Health News:Stem Cells from Fat Outperform Those from Bone Marrow in Fighting Disease 3
... fears associated ... with common diabetes complication, ALEXANDRIA, Va., Oct. 4 ... ghosts and,goblins. But for some, there is something that is ... is a diabetes complication for both men and women.,According to ...
... N.J., Oct. 4 The National Confectioner,s,Association has ... go trick-or-treating,this year. With this in mind, Halloween ... brushing habits to their children. "Since candy ... eating on Halloween. Kids can enjoy chocolate and,lollipops ...
... benefit management ... organizations, ST. ... pharmacy benefit management, announced today it has,achieved URAC Pharmacy Benefit Management ... encourage PBM,industry best practices, promote quality improvement and protect and,empower consumers. ...
... 3 The following is a,statement by Michael Bender, ... credit, the US Food and Drug Administration and its ... a considerable,number of years to present a balanced and ... They recognized that there is,there is enough mercury in ...
... 3 EpiCept Corporation,(Nasdaq and OMX Nordic Exchange: ... will be presenting at the 2007 BIO InvestorForum ... at the Palace Hotel in San,Francisco, California. Mr. ... http://www.newscom.com/cgi-bin/prnh/20020513/NYM112LOGO ) The presentation will ...
... be allergic to,work? If you experience symptoms of allergies ... asthma. This disorder is defined as,reversible airflow obstruction caused ... harmful substances while "on the,job," according to the American ... that about 15%, or 1 in 7, of adult ...
Cached Medicine News:Health News:Diabetes in the Bedroom: Scarier than Halloween? 2Health News:Parents can Help Young Superheroes Battle Cavities on Halloween Night 2Health News:Prime Therapeutics Announces URAC Accreditation 2Health News:New Fish Advice Throws Baby Out With the Bath Water, Says Mercury Watchdog Group 2Health News:EpiCept Corporation to Present at the 2007 BIO InvestorForum 2Health News:EpiCept Corporation to Present at the 2007 BIO InvestorForum 3Health News:AAAAI: Asthma on the Job 2Health News:AAAAI: Asthma on the Job 3
MT-BT-5011-25 Prostate seeding needle (set of 25 unloaded needles).,MT-BT-5011-P Prostate seeding needle, pre-plugged and pre-sterilized, unloaded or for use with MEDTECs ASAP™ pre-load seedin...
... offers five classes of resectoscope electrodes ... loops, knife, roller bar & ball, ... only electrodes specifically integrated into the ... removal with minimal bleeding, increased visibility, ...
... and MRO™-2005 Rigid Percutaneous Nephroscopes combine ... throughput capacity with proven MRO performance. ... with small size sheaths. The MRO™-20 ... easy positioning during percutaneous procedures. The ...
... Resectoscope is based on the award winning ... the surgeon to perform TURis - resection ... element, HF cable and electrodes, Olympus OES ... in saline, supporting both, standard TUR and ...
Medicine Products: